A WONDER cancer drug that acts as a “Trojan horse” to sneak into cells has successfully treated six forms of the disease in British trials.
Researchers say it proved effective in patients in the advanced stages of cancer who had stopped responding to other treatments.
Alamy Cancer cells like this face onslaught as the drug acts as a 'Trojan horse' that sneaks into cells and releases a toxic substance that kills them
A significant minority of the tumours shrank or stopped growing for an average of 5.7 months – and up to 9.5 months.
Some 27 per cent of patients with bladder cancer, 27 per cent with cervical cancer, and 14 per cent ovarian cancer benefited.
There were also responses in 13 per cent with oesophageal cancer, 13 per cent non-small cell lung and seven per cent endometrial.
The innovative new drug, called tisotumab vedotin or TV for short, releases a toxic substance to kill cancer cells from within.
The Institute of Cancer Research, London, and The Royal Marsden hospital tested the drug in almost 150 patients.
The results have been so positive it has now progressed to further trials and will be expanded to other types of cancer.
This includes bowel, pancreatic, squamous cell lung and head and neck.
The majority of patients in the early trial had advanced stage cancer, which had spread locally or around the body.
They had already been treated with, and became resistant to, an average of three different types of treatment.
Study leader Prof Johann de Bono said: “What is so exciting about this treatment is that its mechanism of action is completely novel – it acts like a Trojan horse to sneak into cancer cells and kill them from the inside.
“Our early study shows that it has the potential to treat a large number of different types of cancer, and particularly some of those with very poor survival rates.
“TV has manageable side effects, and we saw some good responses in the patients in our trial, all of whom had late-stage cancer that had been heavily pre-treated with other drugs and who had run out of other options.
“We have already begun additional trials of this new drug in different tumour types and as a second-line treatment for cervical cancer, where response rates were particularly high.
“We are also developing a test to pick out the patients most likely to respond.”
The study was published in The Lancet Oncology medical journal.
Alamy The treatment helped 27 per cent of bladder and cervical cancer cases
Millions at risk of cervical cancer as women shun smear tests in record numbers
- GOT a story? RING The Sun on 0207 782 4104 or WHATSAPP on 07423720250 or EMAIL [email protected]